{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:03:57Z","timestamp":1790996637077,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,2,22]],"date-time":"2005-02-22T00:00:00Z","timestamp":1109030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A double\u2010blind, placebo\u2010controlled study with a subsequent open\u2010label phase was conducted in 354 patients with Parkinson's disease (PD) and motor fluctuations under individually adjusted therapy with levodopa. During the double\u2010blind phase 174 patients received pramipexole and 180 placebo. In agreement with previous studies, pramipexole treatment improved UPDRS sum scores of parts II and III by 30% and <jats:italic>off<\/jats:italic> times by approximately 2.5 hours per day. Differences between the treatment groups became significant at a daily dose of 0.75 mg of pramipexole dihydrochloride. We, furthermore, performed post hoc analyses with respect to resting tremor and depression. Patients with pronounced resting tremor derived a clear benefit from pramipexole treatment compared with placebo. In addition, pramipexole significantly improved the subitems motivation\/initiative and depression in a subpopulation with increased Unified Parkinson's Disease Rating Scale I scores at the time of inclusion. There were 262 patients who were subsequently enrolled into the open\u2010label study featuring a maximum duration of up to 57 months. Statistical analysis revealed good long\u2010term efficacy and tolerability of pramipexole. Overall, only a low prevalence of somnolence was found. In summary, this study provides additional level I evidence of the usefulness of pramipexole, suggests a particular tremorlytic and a possible antidepressant action of this compound, and addresses for the first time its efficacy and safety during long\u2010term administration in advanced PD. \u00a9 2005 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.20397","type":"journal-article","created":{"date-parts":[[2005,2,22]],"date-time":"2005-02-22T20:16:38Z","timestamp":1109103398000},"page":"602-610","source":"Crossref","is-referenced-by-count":107,"title":["Long\u2010term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial"],"prefix":"10.1002","volume":"20","author":[{"given":"J. Carsten","family":"M\u00f6ller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"K\u00f6ster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Pezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Provinciali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,2,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199508000-00006"},{"key":"e_1_2_6_3_2","first-page":"225","article-title":"The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease","volume":"45","author":"Molho ES","year":"1995","journal-title":"J Neural Transm"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.1.162"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.4.1060"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1997.03550020057038","article-title":"Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose\u2010ranging study","volume":"278","author":"Parkinson Study Group","year":"1997","journal-title":"JAMA"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.3.724"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.1998.530235.x"},{"key":"e_1_2_6_9_2","first-page":"301","article-title":"Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease","volume":"22","author":"K\u00fcnig G","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.4.436"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.15.1931"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10508"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.9.1908"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.6.713"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007020070020"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10320"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2003.00612.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.8.1392"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.4.455"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.20397","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.20397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:42:11Z","timestamp":1760949731000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.20397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,22]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1002\/mds.20397"],"URL":"https:\/\/doi.org\/10.1002\/mds.20397","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,22]]}}}